Latest News and Press Releases

Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s...

Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. ...

Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to...

U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule:...

Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design...

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and...

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and...

CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) --  ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic...

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences...

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic...